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A B S T R A C T
Apnea of prematurity (AOP) defined as cessation of breathing for 15–20 s, is commonly seen in preterm infants. Caffeine is widely used to treat AOP due to its safety
and effectiveness. Caffeine releases respiratory arrest by competing with adenosine for binding to adenosine A1 and A2A receptors (A1R and A2AR). Long before its use
in treating AOP, caffeine has been used as a psychostimulant in adult brains. However, the effect of caffeine on developing brains remains unclear. We found that A1R
proteins for caffeine binding were expressed in the brains of neonatal rodents and preterm infants (26–27weeks). Neonatal A1R proteins colocalized with PSD-95,
suggesting its synaptic localization. In contrast, our finding on A2R expression in neonatal neurons was restricted to the mRNA level as detected by single cell RT/PCR
due to the lack of specific A2AR antibody. Furthermore, caffeine (200 μM) at a dose twice higher than the clinically relevant dose (36–130 μM) had minor or no effects
on several basic neuronal functions, such as neurite outgrowth, synapse formation, expression of A1R and transcription of CREB-1 and c-Fos, further supporting the
safety of caffeine for clinical use. We found that treatment with CoCl2 (125 μM), a hypoxia mimetic agent, for 24 h triggered neuronal death and nuclear accu-
mulation of HIF-1α in primary neuronal cultures. Subsequent treatment with caffeine at a concentration of 100 μM alleviated CoCl2-induced cell death and prevented
nuclear accumulation of HIF-1α. Consistently, caffeine treatment in early postnatal life of neonatal mice (P4-P7) also prevented subsequent hypoxia-induced nuclear
increase of HIF-1α. Together, our data support the utility of caffeine in alleviating hypoxia-induced damages in developing neurons.
1. Introduction
Apnea of prematurity (AOP), defined as cessation of breathing
for> 20 s, is commonly seen in preterm infants (≤30weeks of gesta-
tion). Preterm infants have a higher incidence of apnea due to ex-
aggerated inhibition of the respiratory rhythm by adenosine signaling
(Mathew, 2011). Methylxanthines, including caffeine, have been used
to treat AOP for 40 years. Caffeine effectively releases this respiratory
arrest by competing with adenosine for binding to adenosine receptors
(Bairam et al., 1987). Clinically, relatively high concentrations of caf-
feine are used to treat AOP. The plasma concentrations of caffeine in
preterm infants during AOP treatment were shown to be 10–100 times
higher than that in infants receiving breast milk from mothers who
drank moderate doses of coffee (Aden, 2011). The efficacy of caffeine
was not evaluated until recently by a multicenter trial led by Erenberg
and colleagues and by the international trial on caffeine for apnea (CAP
trial) (Erenberg et al., 2000; Schmidt, 2005). The CAP trial suggested
that caffeine is beneficial in lowering the incidence of several short-
term morbidities, including bronchopulmonary dysplasia, and im-
proving neurodevelopmental outcomes of premature infants at 18 to
21months of age (Schmidt et al., 2007). These clinical trials not only
validated the use of caffeine in alleviating AOP but also suggested that
neonatal caffeine treatment may be beneficial to neurodevelopment in
preterm infants.
Caffeine has been used to stimulate adult brains as a psychostimu-
lant long before its use in treating AOP (Ferre, 2016; Frary et al., 2005).
It is thought to modulate adult brain activity and plasticity by directly
perturbing the purinergic system and indirectly affecting the trans-
mission of other neurotransmitters (Fredholm et al., 1999). However,
the effects of caffeine on developing brains remain unclear, especially
when preterm infants receive such high concentrations of caffeine
during AOP treatment.
Hypoxic ischemia is one of the major causes of early brain injury,
which affects around 0.1–0.3% of term infants and the incidence in
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preterm infants is 0.1–0.8% (Davidson et al., 2018). Therapeutic stra-
tegies to treat early brain injury include neuroprotective agents and
plasticity enhancing agents for functional recovery. Caffeine has been
suggested to have both effects: 1) caffeine has been suggested to be
neuroprotective in both rodents and preterm infants (Back et al., 2006;
Cunha, 2001; Ferreira and Paes-de-Carvalho, 2001; Fredholm et al.,
2011; Rivkees and Wendler, 2011; Winerdal et al., 2017) (Schmidt
et al., 2007) and 2) caffeine is known to modulate plasticity in adult
brains (Fredholm et al., 1999). We therefore propose that caffeine is a
candidate agent for alleviating the damages caused by hypoxia
ischemia in neonatal brains.
Adenosine A1 and A2A receptors (A1R and A2AR) are the primary
targets of caffeine (Fredholm et al., 1999). Thus, characterizing the
expression of these receptors in neonatal brains is essential before
testing the effects of caffeine for treating early brain injury. A1R and
A2AR can be detected in rat brains at perinatal stages by in situ hy-
bridization and radioactive ligand binding assays, albeit at lower levels
compared to adult brains (Aden et al., 2000, 2001; Rivkees, 1995).
However, the protein expression and subcellular localization of these
receptors in the brain have not been identified in neonatal rodents and
preterm infants. Using an antibody specifically against A1R in wild type
mice, but not in A1R deficient mice, we found that A1R displayed a
punctate staining pattern and were synaptically localized in the brains
of both neonatal mouse pups (postnatal day 3) and preterm infants
(corrected age of 26–27weeks). In contrast to A1R, the localization of
A2AR in neonatal brains remains unclear due to the poor specificity of
tested antibodies against A2AR. Furthermore, we also demonstrated the
safety and therapeutic effects of caffeine on neonatal neurons. We
found caffeine at a concentration of 200 μM did not affect basic neu-
ronal functions, such as 1) expression and distribution of adenosine
receptor, A1R, 2) mRNA levels of transcription factors, CREB-1, c-Fos
and HIF-1α, and 3) neurite outgrowth and synapse formation. Im-
portantly, we found that at a clinically relevant dose, caffeine promoted
survival of primary neurons after hypoxic insults and prevented hy-
poxia-induced accumulation of HIF-1α both in primary culture (100 μM
of caffeine) and in neonatal mouse pups (estimated serum concentra-
tion of caffeine is 26–77 μM).
2. Materials and methods
The protocols for animal experiments were approved by IACUC at
SUNY Downstate Medical Center, Rutgers University and Feinstein
Medical Institute. The use of autopsy specimens of preterm brain tissue
from the neuropathology laboratory was approved by IRB at Cohen
Children's Medical Center.
2.1. Primary neuronal cultures
Primary neuronal cultures were prepared from E18 or P8 rat pups as
described. Briefly, the hippocampus, cerebellum or cortex was dissected
followed by trypsinization and centrifugation. The pellet was then re-
suspended in neuronal culture medium (Neurobasal medium supple-
mented with 2% B27 and 25mM KCl) and seeded at a density of
5× 105 cells/ml (for RT/PCR and immunostaining) or 1×105 cells/ml
(for MTT assays).
2.2. Induction of hypoxia in vitro
Cobalt chloride (CoCl2·6H2O) (Sigma) was used to induce hypoxia in
primary neuronal cultures as previously described (Wu and Yotnda,
2011). Five-day old neuronal cultures were treated with various con-
centrations of CoCl2 (50–125 μM) for 24 h. After washing off the CoCl2,
cultures were replenished with conditioned medium which was sup-
plemented with 100 μM caffeine or vehicle control for an additional
24 h, followed by fixation and analysis.
2.3. Neonatal hypoxia and caffeine treatment in vivo
Mouse pups were given caffeine at a loading dose of 20mg/kg/day
on postnatal day 4 (P4), then 15mg/kg/day for the next 3 days.
Caffeine was dissolved in sterile water and given to mouse pups via
orogastric tube 1.9 french to maintain a serum concentration of caffeine
at 5–15mg/l (approximately 26–77 μM) (Gaytan et al., 2006; Guillet
and Kellogg, 1991). Sham groups were given equal volumes of sterile
water via the orogastric route. In both groups, half of the pups were
exposed to hypoxic environment (8% oxygen) for 20min on P7,
whereas the other half remained in normoxia. Pups were then deeply
anesthetized with a lethal dose of xylazine (30mg/kg)/ketamine
(300mg/kg) and perfused transcardially with 4% PFA.
2.4. Immunostaining
Immunostaining was performed using antibodies against A1R or
A2AR (Antibody Online, GA and Genetex, CA and AbCam, MA), PSD-95
(Santa Cruz, CA), beta-III tubulin (Sigma), AMPA, CREB-1 and syntaxin
(all from Genscript, NJ), HIF-1α (Novus, CO, Genetex, CA and AbCam,
MA) and c-Fos (Gentex, CA and Biorbyt, CA). The immune complexes
were detected by FITC-conjugated anti-mouse antibodies or Cy3-con-
jugated goat anti-rabbit antibodies (Jackson Immunoresearch, PA). The
resulting images were acquired using Axiovert fluorescent microscopy
(primary neuronal cultures), Zeiss LSM710 (mouse brains) or Olympus
Fluoroview 300 (preterm infant brains) confocal microscopy. The
brains of mice deficient in A1R or A2AR were kindly provided by Dr.
William Welch (Georgetown University) and Dr. Bruce Cronstein
(NYU), respectively.
Unless specified, all mouse brains were immunostained using vi-
bratome sections (50 μm thick). For A1R and PSD-95 co-localization
experiments, cryosectioned slices were used. For study of the expression
of A1R in postmortem preterm human brain, tissues were collected from
the autopsy specimens of preterm infants (gestational age of
23–24weeks) who were given caffeine on the first day of life and
continued until death at three weeks of life. These tissues were fixed in
10% formalin, paraffin embedded and sectioned coronally at 6 μm
thick. Following antigen retrieval, sections were incubated with A1R
antibody.
The densitometries of single cell RT-PCR bands and the neurite
length in the acquired images of beta-III tubulin immunostaining were
quantified using NIH ImageJ. The number of A1R, syntaxin and AMPAR
puncta was quantified using the Analyze Particle function of Fiji
ImageJ (size= 30–250, circularity= 0.3–1.0) as previously described
(Muller et al., 2018; Taylor et al., 2010). The pixel intensity of HIF-1α
in the nucleus and cytoplasm was measured using ImageJ.
2.5. MTT viability assay
Primary neurons were seeded at a concentration of 1×105 cells/ml
and cultured for 7 days prior to the addition of 125 μM of CoCl2 for an
additional 24 h. CoCl2 containing medium was then replaced with
conditioned medium in the presence or absence of 100 μM caffeine for
an additional 24 h. Neuronal viability was tested using the MTT assay as
follows.
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] was added to medium at a final concentration of 0.5mg/ml and
incubated with the cells at 37 °0C for 2 h. The resulting purple crystals
(due to the action of mitochondrial reductase) were solubilized with
DMSO and the optical density at 570 nm was subsequently measured.
2.6. Single cell RT-PCR
Glass cover slips coated with poly-L-lysine (Sigma) were cut at di-
mensions of approximately 2×3mm. These cover slips were placed in
24 well tissue culture plates. Primary neurons were then seeded at a
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density of 5×105 cells/ml. After 48 h, caffeine was added to the
medium for an additional 5 days. Based on the morphology, cover
glasses containing single neurons were harvested for RT-PCR as pre-
viously described (Dulac and Axel, 1995; Li et al., 2009). Reactions that
were positive for the expression of GFAP, a glial cell marker, were
discarded. All PCR products were subjected to sequencing analysis. The
primers used to amplify the corresponding fragment of the genes are
listed in the following table.
Gene (Gene bank no.) Primers
Adenosine A1 Receptor (NM64299) F: ACC TGC CTC ATG GTG GCC TG
R: GTA GTA CTT CTG GGG GTC ACC G
Adenosine A2A Receptor (AF2228684) F: GGA GCT GGC CAT CGC TGT GC
R: TCG CCG CAG GTC TTC GTG GA
Actin (NM031144) F: CCC TGT GCT GCT CAC CGA GG
R: GCG GCA GTG GCC ATC TCT TG
CREB-1 (NM_031017.1) F: GGG CAG ACA GTC CAG GTC CAT
R: GCC AGC TGT ATT GCT CCT CCC
C-Fos (NM_022197) F: ACG AGG CGT CAT CCT CCC GCT
R: CCC TCC TCC GAT TCC GGC AC
HIF-1α (NM_24359.1) F: GCA GCA CGA TCT CGG CGA AGC
R: CAT CGT CCT CCC CCG GCT TG
2.7. Statistics
Data were analyzed using GraphPad Prism 7 software (GraphPad
Software Inc., CA.). Student's t-test was used to compare the data of two
experimental groups, whereas the data of more than two groups were
analyzed by ANOVA. The values of p < 0.001 were considered statis-
tically significant. All data are shown as mean ± SEM.
3. Results
3.1. Adenosine A1 receptors are synaptically localized in neonatal brains
We first asked whether the brains of both neonatal mice and pre-
term infants express the primary receptors for caffeine, adenosine re-
ceptors A1R and A2AR by immunostaining. We chose immunostaining
instead of Western blotting because Western blotting does not show the
subcellular localization of these receptors and the tissue extracts often
include non-neuronal cell types.
We screened the specificity of several commercially available anti-
bodies against A1R and A2AR. We chose antibodies that showed high
immunoreactivity in wild type mouse brains but not in the brains of the
corresponding knockout mice. Using two antibodies against different
epitopes of A1R, we consistently observed A1R distributed in a punc-
tuate pattern in adult wild type brains (25.33 ± 2.40 puncta), but not
in A1R-deficient brains (8.67 ± 0.88 puncta, p < 0.001) (Fig. 1A, top
panel; enlarged images are in Supplementary Fig. S1A).
In contrast to A1R, several commercially available antibodies
against A2AR displayed low specificity, showing intense nuclear
staining in both wild type and A2AR knockout brains (Fig. 1A, bottom
panel; enlarged images are in Supplementary Fig. S1A). Thus, this study
focused mainly on A1R, but not A2AR, in neonatal brains.
Similar to adult brain tissues, we found A1R also distributed in a
punctate pattern in neonatal cortex (Fig. 1B). This punctate pattern can
be detected in neonatal mouse cortex as early as postnatal day 3 (P3),
albeit the puncta are smaller in size compared to those in older pups
(P10 and 1month old) (Fig. 1B; an enlarged image of P3 brain is in
Supplementary Fig. S1B). In addition to cortex, A1R was also expressed
in a similar punctate pattern in various brain regions, such as medulla,
cerebellum, thalamus and hippocampus (Fig. 1C; an enlarged image of
medulla is in Supplementary Fig. S1C). A1R puncta were most promi-
nent in medulla and cerebellum (Fig. 1C), but weak in basal ganglia
(data not shown). The punctuate pattern of A1R is reminiscent of that of
synaptic markers. Using double immunostaining, we found that A1R co-
localized with PSD-95, a synaptic protein, suggesting A1R is synapti-
cally localized in neonatal mouse brain (the earliest time point we
studied is P3) (Fig. 1E, top panel; an enlarged image is in Supplemen-
tary Fig. S1E).
We next sought to extend our findings to postmortem preterm
brains. Most deceased preterm infants in our clinics were born at ap-
proximately gestational age of 23–24weeks and died at the corrected
age of 26–27weeks. Among these patients, we selected infants with no
discernible brain abnormalities on head ultrasound. It is worth noting
that all selected infants received caffeine since it is our policy that all
preterm infants with gestational age younger than 29weeks be given
caffeine within hours after birth. We therefore did not have age-mat-
ched preterm infants who did not receive caffeine among this age
group. However, we still found detectable levels of A1R puncta in these
preterm brains, as demonstrated in the cortex of 6 different preterm
infants (a representative section of each patient is shown in Fig. 1D; an
enlarged image is in Supplementary Fig. S1D). These A1R puncta co-
localized with PSD-95 (Fig. 1E, bottom panel). Together, these data
supported the hypothesis that the preterm brain may be influenced by
caffeine during therapy to treat AOP.
3.2. Caffeine promotes cell survival and suppresses hypoxia-induced nuclear
accumulation of HIF-1α in vitro
Caffeine has been suggested to be neuroprotective, but its safety and
effectiveness in neonatal neurons remained unclear (Aden, 2011;
Natarajan et al., 2007; Rivkees and Wendler, 2011; Schmidt et al.,
2007; Winerdal et al., 2017). Here, we sought to address these issues
both in vitro and in vivo. When investigating whether caffeine perturbs
the general neuronal functions, we used a higher concentration of
caffeine (200–400 μM). However, we returned to the clinically relevant
doses of caffeine (50–100 μM) to evaluate its neuroprotective effects on
primary neurons after ischemic insults.
We examined three neuronal aspects to gauge the safety of caffeine:
1) expression of A1R and A2AR, 2) levels of several transcription factors,
CREB-1, c-Fos and HIF-1α, and 3) synapse formation and neurite out-
growth. First, we analyzed the effects of caffeine on the transcription of
A1R and A2AR by single cell RT/PCR as well as their protein levels by
immunostaining. To ensure specificity, all RT/PCR products were se-
quenced to verify the identity of adenosine A1R and A2AR. The in-
tensities of the PCR products were quantified using the densitometry
function of ImageJ in arbitrary units. We found that neonatal neuronal
cultures expressed mRNA for both adenosine A1R and A2AR in un-
treated controls (2104 ± 138 and 2446 ± 130). With 200 μM caffeine
treatment, the transcription of A1R and A2AR was comparable to that of
untreated neurons (2000 ± 136 and 2500 ± 150). However, when
the concentration of caffeine was raised to 400 μM, caffeine selectively
impaired the transcription of A1R, but not A2R (360 ± 0.3 and
2280 ± 77) (Fig. 2A). Second, caffeine treatment was suggested to
regulate the expression of several transcription factors, such as c-Fos,
CREB-1, and HIF-1α (Connolly and Kingsbury, 2010; Gaytan and
Pasaro, 2012) (Maugeri et al., 2018; Merighi et al., 2007). CREB-1 and
c-Fos are immediate early genes induced by neural activity, whereas
HIF-1α is often induced by hypoxic conditions. We examined the effects
of caffeine on these transcription factors in neuronal cultures under
normoxic conditions using single cell RT/PCR. In the absence of caf-
feine, there was low baseline expression of c-Fos but higher levels in
HIF-1α and CREB-1 mRNA (HIF-1α, 2978 ± 17.5; CREB-1,
2928 ± 64; c-Fos, 105 ± 7.5) (Fig. 2A). With treatment of either
200 μM or 400 μM caffeine, we did not observe any significant changes
in the transcription of HIF-1α, CREB-1 and c-Fos (HIF-1α, 3141 ± 193
and 3095 ± 111; CREB-1, 2933 ± 88 and 3007 ± 64; c-Fos,
132 ± 7.6 and114 ± 4) (Fig. 2A). Third, beta-III tubulin and syntaxin
are commonly used markers for the measurement of neurite length and
synaptogenesis (Katsetos et al., 2003; Shin, 2014). We found that the
average neurite length (162.1 ± 17.45 μm) and the number of
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Fig. 1. (continued)
Fig. 1. The brains of neonatal mice and preterm infants expressed A1R receptors. (A) Immunostaining results showed the specificity of A1R antibody but not A2AR
antibody. Using the tested A1R antibody, A1R immunostaining showed a punctate distribution of this receptor in the cortex of wild type adult mice, but not in that of
A1R deficient mice (25.33 ± 2.4 and 8.67 ± 0.88 puncta, respectively) (top). In contrast, several antibodies against A2AR showed non-specific immunoreactivity in
the nucleus and the cytoplasm in both wild type and A2AR deficient mice (bottom). No punctate pattern was observed (6 ± 1.53 puncta for WT and 4.33 ± 0.3
puncta for A2AR knockout). Representative images are shown here. The quantitative results are shown on the right. Blue arrows indicate puncta. Scale bar, 10 μm. (B)
The punctate pattern of A1R could be detected in the cortex of P3 pups. The A1R puncta appeared more discrete at a lower magnification as the animals mature
(10 day-old and 1month-old pups). (C) A1R distributed in a punctate pattern in medulla, cerebellum, thalamus and hippocampus. The puncta were more prominent
in medulla and cerebellum. Scale bar, 20 μm. (D) Immunostaining showed a punctate pattern of A1R in the cortex of preterm infants at the corrected age of
26–27 weeks. Representative images of the cortex from 6 preterm brains are shown. Scale bar, 10 μm. (E) A1R colocalized with a synaptic protein, PSD-95, in frozen
sections of neonatal mouse brain (upper panel) and paraffin sections of preterm infant brains (lower panel). Scale bar, 20 μm. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 2. (A) Treatment with 200 μM caffeine has minimal/no effect on the transcription of A1R and A2AR, HIF-1α, CREB-1 or c-Fos in vitro. Single cell RT/PCR was
performed on neuronal culture that were treated with or without caffeine for 5 days (n=10). The intensities of the RT-PCR bands were quantified by densitometry in
arbitrary units. The results of control and caffeine groups are as follows: A1R (2104 ± 138, 2000 ± 136), A2AR (2446 ± 130, 2500 ± 150), HIF-1α
(2978 ± 17.5, 3141 ± 19.3), CREB-1 (2928 ± 64, 2933 ± 88) and c-Fos (105 ± 7.5, 132 ± 7.6). The levels of β-actin were used as a loading control. The
transcription levels of CREB-1 and HIF-1α were discernible, but the level of c-Fos was barely detectable. A high dose of caffeine (400 μM) selectively decreased the
transcription of A1R (36 ± 0.3, p < 0.001) but not other tested factors. (B) Treatment with 200 μM caffeine did not affect neurite length (beta-III tubulin, red)
(184.9 ± 27.16 μm for control and 162.1 ± 17.45 μm for caffeine treatment group) and synapse formation (syntaxin, green) (14.67 ± 1.45 for control and
15.33 ± 1.76 for caffeine treatment group). The quantitative results are shown on the right. Scale bar, 100 μm (n=5). (For interpretation of the references to colour
in this figure legend, the reader is referred to the web version of this article.)
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syntaxin puncta (15.33 ± 1.76) in neurons that were treated with
200 μM caffeine for 5 days is comparable to that of the untreated neu-
rons (184.9 ± 27.6 μm and 14.67 ± 1.45, respectively) (Fig. 2B).
Together, our data defined the safety threshold for caffeine at 200 μM
since this dose did not perturb basic neuronal functions and char-
acteristics in vitro.
We next sought to determine whether caffeine treatment promotes
neuronal survival after hypoxic ischemia. Many of the cellular re-
sponses induced by hypoxia are mediated by changes in gene
expression, which are often regulated by HIF-1α (Ke and Costa, 2006;
Semenza, 2007; Shi, 2009). Under normal conditions, HIF-1α is con-
stitutively degraded by prolyl-hydroxylase enzymes. However, hypoxia
stabilizes HIF-1α by inhibiting these enzymes. Cobalt chloride (CoCl2)
is a hypoxia mimetic agent in vitro since it also inhibits prolyl-hydro-
xylase enzymes, resulting in accumulation and nuclear translocation of
HIF-1α (Li et al., 2015; Piret et al., 2002). Here, we used CoCl2 to mimic
hypoxia in vitro. Primary neurons (5–7 days in culture) were treated
with 50–125 μM CoCl2 for 24 h as previously described (Wu and
Fig. 3. Caffeine promoted cell survival after
hypoxia and decreased CoCl2-induced nu-
clear accumulation of HIF-1α in vitro. (A)
Primary cortical neuronal cultures were
treated with CoCl2 or vehicle (control) for
24 h. Each group was divided into two sub-
groups that were either treated with 100 μM
caffeine or vehicle for an additional 24 h.
The viability of each treatment group was
subsequently measured by MTT assays. Data
are presented as percentage of viability in
each group relative to that of the control
group (control, 100%; caffeine alone,
94 ± 7.1%; CoCl2 treatment, 65.6 ± 3.6%;
CoCl2+ caffeine, 87.2 ± 10.5% n=4.
p < 0.001).(B) Treated neurons were
double-immunostained to label HIF-1α
(green, top row) and neuron-specific beta-III
tubulin (red, not shown) and counter-stained
with DAPI for nuclei (blue, middle row). The
merged images of HIF-1α and DAPI are
shown in the bottom row. Beta-III tubulin
immunostaining (not shown) was used as a
neuronal marker. In the absence of CoCl2,
HIF-1α was primarily localized in the cyto-
plasm regardless of whether neurons re-
ceived caffeine or not (Lane 1, a, b, c and
Lane 2, d, e, f). In contrast, CoCl2 triggered
nuclear co-localization of HIF-1α with DAPI
(Lane 3, g.h.i), suggesting nuclear accumu-
lation of HIF-1α. White arrows indicate co-
localization of HIF-1α and DAPI. This nu-
clear accumulation of HIF-1α was alleviated
by subsequent treatment with caffeine (Lane
4, j, k,l). Scale bar, 20 μm. (C) Quantification
of the ratio of nuclear vs cytoplasmic HIF-1α
in neurons of each treatment group (control,
0.73 ± 0.07; caffeine alone, 0.78 ± 0.03;
CoCl2 treatment, 1.81 ± 0.17, CoCl2 and
caffeine, 0.82 ± 0.04, p < 0.001, n=5).
(For interpretation of the references to
colour in this figure legend, the reader is
referred to the web version of this article.)
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Yotnda, 2011). The culture medium was discarded and replenished
with conditioned medium in the presence or absence of 100 μM caffeine
for an additional 24 h. Subsequently, cells were subjected to MTT assay
to measure cell survival rate (Denizot and Lang, 1986). In this experi-
ment, the MTT reading of control group (no treatment) was defined as
100% viability. The MTT readings of other groups were compared with
that of the control group, and the percentage of viability was derived
accordingly. We found that the viability of neuronal cultures was
comparable in the presence or absence of caffeine (Fig. 3A; control,
100%; caffeine alone, 94 ± 7.1%), suggesting caffeine does not affect
baseline cell survival. As expected, CoCl2 decreased the viability of
neuronal cultures compared to that of untreated cultures (Fig. 3A;
CoCl2 treatment, 65.6 ± 3.6%, p < 0.001). Interestingly, the low
viability caused by CoCl2 was alleviated significantly by subsequent
treatment with 100 μM caffeine (Fig. 3A; CoCl2+ caffeine,
87.2 ± 10.5%, n= 4, p < 0.001).
HIF-1α appears to have complex effects in hypoxic brains in a time-
dependent manner (Supplementary Table S1). Accumulation of HIF-1α
after ischemia has been shown to facilitate cell death at the very early
phase (< 24 h, pro-death effect) (Barteczek et al., 2017; Cheng et al.,
2014; Yang et al., 2017), but HIF-1α has also been shown to limit in-
farct size at a later stage (> 4 d, pro-survival effect) (Baranova et al.,
2007; Bergeron et al., 2000; Sheldon et al., 2009, 2014). Since caffeine
treatment increased neuronal viability immediately after hypoxia, we
hypothesized that caffeine could decrease the accumulation of HIF-1α,
therefore inhibiting its pro-death effect. To test this hypothesis, neu-
ronal cultures were treated as in Fig. 3A. We then co-immunostained
the neuronal culture with 1) antibody against beta-III tubulin for neu-
ronal labeling, 2) antibody against HIF-1α transcription factor and 3)
DAPI for nuclear staining. The ratio of the pixel intensity of HIF-1α
immunostaining in the nucleus vs cytoplasm of the neurons was com-
puted using Image J. Prior to the induction of hypoxia, the ratio of
nuclear vs cytoplasmic HIF-1α is comparable in cultures treated with
100 μM caffeine or vehicle (0.78 ± 0.03 and 0.73 ± 0.07, respec-
tively) (Fig. 3B and C, Lane 1 and 2), suggesting that caffeine alone did
not affect nuclear levels of HIF-1α. However, this ratio increased sig-
nificantly in CoCl2-treated cultures (1.81 ± 0.17, p < 0.001) com-
pared to that of untreated cultures, suggesting nuclear accumulation of
HIF-1α in CoCl2-induced hypoxia (Fig. 3B and C). For most of the study,
we used 125 μM CoCl2 since this concentration triggered a significant
nuclear accumulation of HIF-1α and cell death (Fig. 3B and C). Inter-
estingly, subsequent treatment with 100 μM of caffeine alleviated this
hypoxia-induced nuclear accumulation of HIF-1α (0.82 ± 0.04,
p < 0.001) (Fig. 3B and C).
3.3. Caffeine suppresses hypoxia-induced nuclear accumulation of HIF-1α
factor in vivo
We next sought to examine whether caffeine treatment in newborn
mice is neuroprotective for subsequent hypoxia exposure. Here, caf-
feine was given to neonatal pups before induction of hypoxia in order to
1) avoid the high mortality rate when carotid ligation is performed in
newborn mice at the age of P0-P4, and 2) avoid the injury-induced
plasticity obscuring the potential effects of caffeine on neuroprotection
and 3) mimic the timing of caffeine therapy in preterm infants.
Neonatal pups were gavage fed with caffeine as previously de-
scribed (Gaytan et al., 2006). After caffeine treatment, the animals were
exposed to a hypoxic or normoxic environment for 20min before eu-
thanization (Zaghloul et al., 2014). Their brains were removed im-
mediately after the procedure and the brain sections were im-
munostained with HIF-1α antibody and counter stained with DAPI.
We first ensured caffeine treatment did not perturb basic neuronal
functions. We found that the expression and subcellular localization of
A1R in various brain areas were similar whether neonatal pups received
caffeine or not (Fig. 4A, the puncta number in cortex is 70 ± 1.15 in
control group and 67.3 ± 1.86 in caffeine group). Caffeine treatment
also did not affect the punctate pattern of A1R in cerebellum and brain
stem (data not shown). In addition, we did not observe any significant
changes in immunostaining for AMPA receptors, CREB-1 and c-Fos in
the brains of neonatal rodents that were treated with vehicle or caffeine
(AMPAR puncta, 67.6 ± 2 and 63.6 ± 2; CREB-1, 79 ± 2.1,
81.3 ± 1.5; c-Fos, 1 ± 0.58, 1 ± 0.1, respectively) (Fig. 4A; an en-
larged image of AMPA receptor puncta is in Supplementary Fig. S3).
Together, these data suggested that this clinically relevant dose of
caffeine did not have a discernible impact on A1R expression and the
protein levels of AMPAR, CREB-1, and c-Fos.
Under normoxia, caffeine treatment did not affect the ratio of nu-
clear vs cytoplasmic HIF-1α in the brain of P7 pups whether the animals
received caffeine or not (0.71 ± 0.05 for control group and
0.77 ± 0.03 for caffeine treatment group) (Fig. 4B and C, Lane 1 and
2). Hypoxia increased the ratio of nuclear vs cytoplasmic HIF-1α in P7
pups that did not receive caffeine therapy (1.33 ± 0.05, p < .001)
(Fig. 4B and C, Lane 3). In contrast, the same hypoxic condition failed
to trigger a significant nuclear accumulation of HIF-1α in neonatal pups
that had received caffeine feeding previously (the ratio of nuclear vs
cytoplasmic HIF-1α is 0.9 ± 0.02, p < .001) (Fig. 4B and C, Lane 4),
suggesting a prophylactic effect of caffeine in preventing upregulation
in HIF-1α by subsequent hypoxia.
4. Discussion
Caffeine therapy is widely used to treat AOP because of its ef-
fectiveness and safety. Caffeine relieves AOP by competing with
adenosine for binding to its receptors, A1R and A2AR, in brain stem.
However, the effects of caffeine at this high dose on neonatal brains
remained unclear. In this study, we first showed that the neonatal
brain of both rodents and preterm infants expressed A1R and that
this receptor was enriched in synapses. In addition, we also detected
A2AR mRNA by single cell RT/PCR in primary neuronal cultures.
These data suggested that neonatal brains could be responsive to
caffeine via A1R and potentially A2AR. We then showed that caffeine
was considered safe in neonatal neurons since it did not perturb
several basic neuronal functions, including the expression and dis-
tribution of A1R, transcription of CREB-1, c-Fos and HIF-1α and
neurite outgrowth and synapse formation. Lastly, we determined the
beneficial effects of caffeine in alleviating hypoxia-induced neuronal
death. We found that caffeine at clinically relevant doses suppressed
hypoxia-induced nuclear accumulation of HIF-1α both in vitro and
in vivo, and promoted viability in neuronal cultures exposed to
hypoxia.
4.1. A1R is synaptically localized in neonatal brains
The major receptors for caffeine are adenosine A1R and A2AR
(Aden et al., 2000; Fredholm, 1995). However, the protein expression
and subcellular localization of these receptors in developing neurons
remain unclear. We found that the brains of neonatal mice and de-
ceased preterm infants expressed A1R in brain areas, such as cortex,
basal ganglia, thalamus, and hippocampus. We also found A1R was
enriched in synapses. The synaptic targeting of A1R began at neonatal
stages, albeit to a lesser extent, since the A1R puncta became more
prominent as the mouse pups matured into adulthood (Fig. 1B). In-
terestingly, the synaptic targeting of A1R is functionally linked to its
neuromodullatory role in the adult brain (Rebola et al., 2003; Sheth
et al., 2014).
In contrast to A1R, we found A2AR mRNA by single cell RT/PCR was
expressed in neonatal neuronal culture, but the protein distribution of
A2AR in neonatal brains remained unclear. Previous reports showed
soma enrichment of A2AR in the respiratory nuclei of neonatal brain
stem (Gaytan and Pasaro, 2012). We also observed soma/nuclear en-
richment of A2AR by immunostaining, but unfortunately, this strong
immunostaining was present in both wild type brains and A2AR
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deficient brains, rendering inconclusive results (Fig. 1A). As a control,
we also tested these antibodies in adult brains since radio-ligand
binding assays have clearly shown that the expression of A2AR is more
enriched in striatum and olfactory bulb in adult brains (Fredholm et al.,
2011), but none of these commercial antibodies showed this im-
munostaining pattern in adult brains.
4.2. Clinically relevant doses of caffeine had minor/no effects on synapse
formation and expression of A1R, CREB-1 and c-Fos
Caffeine has been shown to regulate the synaptic functions in adult
cortical regions in several in vitro experiments (Greene et al., 1985;
Yoshimura, 2005). However, we did not observe any differences in
neurite length, synaptic density or the expression of several
(caption on next page)
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transcription factors between caffeine-treated and untreated neonatal
neuronal culture. Moreover, under normoxic condition, the morphology
of neonatal brains from pups receiving caffeine treatment appeared
similar to that from untreated group.
A previous study has shown that caffeine increased A1R transcrip-
tion in the brain stem and the respiratory nuclei of the hypothalamus
when caffeine was given to neonatal pups directly (Gaytan and Pasaro,
2012). The same study also demonstrated a caffeine-induced early shift
of the postnatal increase in c-Fos in these regions. However, in our
study, we did not observe any changes in 1) the protein levels of A1R in
the neonatal cortex and other regions (hippocampus/medulla/cere-
bellum/thalamus), and 2) the transcription levels of A1R in neuronal
cultures. We also found that the protein levels of c-Fos were low in both
control and caffeine-treated groups. Since we also fed neonatal pups
with caffeine directly or added caffeine into neuronal cultures directly,
this discrepancy may arise from analyzing different brain regions and
using different methodology. For example, we used single cell RT-PCR
to analyze pure neuronal population, whereas Gaytan and colleagues
used qPCR to analyze the whole extracts of hypothalamus and re-
spiratory nuclei.
Fig. 4. (continued)
Fig. 4. Caffeine blocked hypoxia-induced nuclear accumulation of HIF1-α in vivo. (A) Immunostaining for A1R, AMPA receptors, CREB-1 and c-Fos showed that
caffeine treatment has minimal/no effect on the expression of these factors in neonatal cortex (n=5). Scale bar, 20 μm. The quantitative results in control and
caffeine-treated groups are shown on the right; the number of A1R (70 ± 1.15, 67.3 ± 1.86) or AMPA receptor puncta (67.6 ± 2, 63.6 ± 2), the number of
nuclear CREB-1 (79 ± 2.1, 81.3 ± 1.5) or c-Fos (1 ± 0.58, 1 ± 0.01). (B) Neonatal mouse pups were gavage fed with caffeine or vehicle from P4-P7.
Subsequently, pups were placed under normoxic (room air) or hypoxic (8% O2) conditions for 20min prior to cardiac perfusion and isolation of their brains. Brain
sections were immunostained with anti-HIF-1α (green, top row) and counter-stained with DAPI to show nuclei (blue, middle row). The overlaid images of HIF-1α
immunostaining and DAPI staining are shown in the bottom row. Representative cortical images are shown here. Under normoxic conditions, HIF-1α primarily
distributed in the cytoplasm of cortical neurons whether mouse pups received caffeine therapy or not (Lane 1, a. b. c. and Lane 2, d, e, f). In pups without caffeine
therapy, hypoxia induced nuclear accumulation of HIF-1α (Lane 3, g, h, i). White arrows indicate co-localization of HIF-1α and DAPI. Pre-treatment with caffeine
prevented subsequent hypoxia-induced nuclear accumulation of HIF-1α in neonatal cortex (Lane 4, j, k, l). Scale bar, 20 μm. (C) Quantification of the ratio of nuclear
vs cytoplasmic HIF-1α in neonatal cortex in each group (control, 0.71 ± 0.05; caffeine alone, 0.77 ± 0.03; hypoxia, 1.33 ± 0.05; hypoxia and caffeine,
0.9 ± 0.02, p < 0.001, n= 5). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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4.3. Caffeine blocks hypoxia-induced nuclear accumulation in HIF-1α and
promotes neuronal survival
It has been suggested that caffeine has opposite effects on em-
bryonic vs neonatal brains because caffeine is a potent inhibitor of A1R.
During the embryonic stage, inhibition of A1R rendered cells more
susceptible to hypoxia, whereas inhibition of A1R in neonatal brains
after birth was neuroprotective in white matter injury and hypoxic
ischemia in rodents (Rivkees and Wendler, 2011). Notably, caffeine
therapy for AOP and most related research in neonatal rodents em-
ployed postnatal treatment. Thus, caffeine has been suggested to have
neuroprotective effects during the neonatal period (Back et al., 2006;
Cunha, 2001; Ferreira and Paes-de-Carvalho, 2001; Fredholm et al.,
2011; Rivkees and Wendler, 2011; Winerdal et al., 2017) and are
beneficial to neurodevelopment in preterm infants (Murner-Lavanchy
et al., 2018; Schmidt et al., 2007).
Here, we showed a novel mechanism by which caffeine exerts its
neuroprotective effects in neonatal brains. Hypoxia generally results in
tissue damage immediately after ischemia. The “pro-death” effect of
HIF-1 at this stage has been shown to facilitate death of severely injured
neurons (Supplementary Table S1) (Barteczek et al., 2017; Cheng et al.,
2014; Liu et al., 2015; Yang et al., 2017). We found that caffeine alle-
viated hypoxia-induced accumulation of HIF-1α both in vivo and in vitro
and therefore increased the viability of primary neurons. This in-
hibitory effect is specific to nuclear accumulation of HIF-1α, not on its
transcription (Supplementary Fig. S2). In addition, caffeine had neu-
roprotective effects in vivo whether caffeine was administered before or
after hypoxic insults. A recent study showed that a single dose of caf-
feine (5mg/ml via intraperitoneal injection) immediately after neonatal
hypoxic ischemia in neonatal pups decreased brain atrophy and im-
proved behavioral outcomes at 2 weeks after hypoxic insults (Winerdal
et al., 2017). However, in our study, caffeine was given to neonatal
pups (P4-P7) before induction of mild hypoxia (8% O2 in 20min). We
found that early caffeine therapy could prevent subsequent hypoxia-
induced accumulation of HIF-1α. Clinically, our data suggest that caf-
feine therapy in the NICU may protect preterm brains from hypoxic
damages that may occur during their NICU stay.
In conclusion, our results further support the utility of caffeine in
preventing hypoxia-induced nuclear accumulation of HIF-1α and pro-
motes neuronal survival.
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